• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table G-24Placebo-controlled trials of alpha-blockers

Domains Pertaining to Strength of EvidenceMagnitude of EffectStrength of Evidence
Number of Studies; Number of SubjectsRisk of Bias; Design/QualityConsistencyDirectnessPrecisionSummary Effect Size (95% CI)High, Moderate, Low, Insufficient
PTSD Symptom Reduction: CAPS
2; 50Medium; RCTsConsistent (I2 1.8%)DirectImpreciseWMD −8.86 (−22.06 to 4.33)Insufficient
Remission (no longer having symptoms)
0; 0NANANANANAInsufficient
Loss of Diagnosis
0; 0NANANANANAInsufficient
Prevention/reduction of comorbid depression
1; 40Medium; RCTNA, single studyDirectImprecise−5.6 vs. −0.6, p=0.08Insufficient
Prevention/reduction of comorbid anxiety
0; 0NANANANANAInsufficient
Quality of Life
0; 0NANANANANAInsufficient
Disability/functional impairment
0; 0NANANANANAInsufficient
Return to work or return to active duty
0; 0NANANANANAInsufficient

Abbreviations: CI = confidence interval; NA = not applicable; RCT = randomized controlled trial

From: Appendix G, Strength of Evidence

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.